NEW YORK, May 31, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please
scroll to bottom.
Today, Wall Street Reports announced new research reports
highlighting Gilead Sciences, Inc. (NASDAQ: GILD), Biogen Idec Inc.
(NASDAQ: BIIB), GlaxoSmithKline plc. (ADR) (NYSE: GSK), Viropharma
Inc. (NASDAQ: VPHM), and Celsion Corporation (NASDAQ: CLSN).
Today's readers may access these reports free of charge - including
full price targets, industry analysis and analyst ratings - via the
links below.
Gilead Sciences, Inc. Research
Report
On May 28, 2013, Gilead Sciences,
Inc. (Gilead) announced that the European Commission has granted
marketing authorization for Stribild (elvitegravir 150
mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil (as
fumarate) 245 mg), a single tablet regimen for HIV-1 infection in
adults who are antiretroviral treatment-naïve or infected with
HIV-1 without known mutations associated with resistance to any of
the three antiretroviral agents in Stribild. Jürgen Rockstroh, MD,
Professor of Medicine, University of Bonn, Germany and a Lead Investigator for one of the
Stribild pivotal studies, commented, "Single tablet regimens make
it easier for HIV patients to take their treatment consistently
every day, which may improve their health outcomes. Stribild is a
highly effective and well tolerated HIV treatment regimen, and is
an important addition to the growing arsenal of simplified
therapies in Europe." This
approval allows the Company to market Stribild in all 27 countries
of the European Union. Stribild is the third single tablet HIV
regimen developed by the Company to become available in
Europe, after Atripla and
Eviplera. Stribild is also approved in the United States, Canada, Australia, South
Korea, Japan, and
Turkey. The Full Research Report
on Gilead Sciences, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free
of charge at:
[http://www.wsreports.com/r/full_research_report/9696_GILD]
Biogen Idec Inc. Research Report
On May 23, 2013, Biogen Idec Inc.
(Biogen Idec) announced the appointment of Spyros
Artavanis-Tsakonas, Ph.D., as the Company's Chief Scientific
Officer (CSO). Dr. Artavanis-Tsakonas previously served as the
Company's Chief Scientific Officer on an interim basis while on
sabbatical from Harvard Medical School.
He will now resume his role in a permanent capacity, and will also
lead the Company's research strategy, capabilities, and discovery
platforms. Doug Williams, Biogen
Idec's Executive Vice President of Research and Development, said,
"He will continue what he has successfully started at Biogen
Idec-attracting and encouraging exceptional scientific talent,
enhancing our existing early discovery programs, establishing
extensive academic collaborations and leading our drug discovery
strategy." The Full Research Report on Biogen Idec Inc. - including
full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/b35f_BIIB]
GlaxoSmithKline plc. (ADR) Research
Report
On May 22, 2013, GlaxoSmithKline
plc. (ADR) (GSK) and the Biomedical Advanced Research and
Development Authority (BARDA), a segment of the U.S. Department of
Health and Human Services (HHS), announced a first-of-its-kind
collaboration that will support the development of several
antibiotics to fight antibiotic resistance and bioterrorism. Under
the terms of the agreement, HHS will provide $40 million for the initial 18-month agreement
and up to $200 million if the
agreement is renewed over five years. According to the GSK, this
collaboration provides flexibility to move around GSK's
antibacterial portfolio, rather than focusing on just one drug
candidate and allow medicines to be studied for the potential
treatment of both conventional and biothreat pathogens. The Full
Research Report on GlaxoSmithKline plc. (ADR) - including full
detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/2737_GSK]
Viropharma Inc. Research Report
On May 28, 2013, Viropharma, Inc.
(Viropharma) announced results of data analyses from the
randomized, placebo-controlled, and open label clinical trials of
Cinryze (C1 esterase inhibitor [human]). The results showed the
effectiveness of Cinryze in prevention of angioedema attacks in
patients with Hereditary Angioedema (HAE). Dr. Zuraw, Professor of
Medicine, Chief of Section of Allergy and Immunology, and Director
of the Allergy and Immunology Training Program at the University of California, said, "While clinical
trials have demonstrated the efficacy and safety of Cinryze for the
long-term prevention of HAE, these data demonstrate that Cinryze is
an important option, even in patients who have been managed on
anabolic androgens and continue to experience multiple attacks of
HAE." The Full Research Report on Viropharma Inc. - including full
detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/cf37_VPHM]
Celsion Corporation Research
Report
On May 22, 2013, Celsion
Corporation (Celsion) announced that its proprietary patent
application, "Method of Storing Nanoparticle Formulations," has
been granted in China,
Japan, South Korea, and Taiwan, the four largest markets for liver
cancer in the world. The Company holds an exclusive agreement with
Duke University for its temperature
sensitive liposome technology which covers the ThermoDox
formulation. These newly issued patents pertain to methods of
storing stabilized, temperature-sensitive liposomal formulations,
and will assist in the protection of global rights by extending the
overall term of the ThermoDox patent portfolio to August 2026. The Full Research Report on Celsion
Corporation - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/ebef_CLSN]
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by a CFA. However, we are only
human and are prone to making mistakes. If you notice any errors or
omissions, please notify us below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquires, please contact us
at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Equity News Network. An outsourced research services provider has,
through Chartered Financial Analysts, only reviewed the information
provided by Equity News Network in this article or report according
to the Procedures outlined by Equity News Network. Equity News
Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as
to the accuracy or completeness or fitness for a purpose
(investment or otherwise), of the information provided in this
document. This information is not to be construed as personal
financial advice. Readers are encouraged to consult their personal
financial advisor before making any decisions to buy, sell or hold
any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may
be occasioned at the time of printing of this document or any
error, mistake or shortcoming. No liability is accepted by Equity
News Network whatsoever for any direct, indirect or consequential
loss arising from the use of this document. Equity News Network
expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Equity News Network
does not (1) guarantee the accuracy, timeliness, completeness or
correct sequencing of the information, or (2) warrant any results
from use of the information. The included information is subject to
change without notice.
SOURCE Wall Street Source